Natera, Inc. (NTRA) Just Reaches 52-Week High?

July 13, 2018 - By Andrea Pope

Natera, Inc. (NASDAQ:NTRA) Logo

The stock of Natera, Inc. (NASDAQ:NTRA) hit a new 52-week high and has $22.32 target or 4.00 % above today’s $21.46 share price. The 5 months bullish chart indicates low risk for the $1.17B company. The 1-year high was reported on Jul, 13 by Barchart.com. If the $22.32 price target is reached, the company will be worth $46.80M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 1.87% or $0.41 during the last trading session, reaching $21.46. About 313,402 shares traded. Natera, Inc. (NASDAQ:NTRA) has risen 12.60% since July 13, 2017 and is uptrending. It has outperformed by 0.03% the S&P500.

Analysts await Natera, Inc. (NASDAQ:NTRA) to report earnings on August, 14. They expect $-0.53 EPS, down 1.92 % or $0.01 from last year’s $-0.52 per share. After $-0.61 actual EPS reported by Natera, Inc. for the previous quarter, Wall Street now forecasts -13.11 % EPS growth.

Natera, Inc. (NASDAQ:NTRA) Ratings Coverage

Among 4 analysts covering Natera (NASDAQ:NTRA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Natera has $20 highest and $16 lowest target. $19’s average target is -11.46% below currents $21.46 stock price. Natera had 8 analyst reports since March 14, 2018 according to SRatingsIntel. Morgan Stanley maintained the shares of NTRA in report on Wednesday, May 9 with “Overweight” rating. Morgan Stanley maintained the shares of NTRA in report on Monday, June 25 with “Overweight” rating. The stock of Natera, Inc. (NASDAQ:NTRA) has “Buy” rating given on Monday, June 25 by Canaccord Genuity. On Friday, June 22 the stock rating was maintained by Craig Hallum with “Buy”. Robert W. Baird maintained it with “Buy” rating and $17.0 target in Wednesday, March 14 report. Robert W. Baird maintained Natera, Inc. (NASDAQ:NTRA) rating on Thursday, June 28. Robert W. Baird has “Outperform” rating and $20 target. The company was maintained on Wednesday, March 14 by Canaccord Genuity.

More news for Natera, Inc. (NASDAQ:NTRA) were recently published by: Seekingalpha.com, which released: “Natera: A Quick Look At A Growing Testing Concern” on June 29, 2018. Fool.com‘s article titled: “Why Natera Inc. Is Rising Today” and published on June 25, 2018 is yet another important article.

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. The company has market cap of $1.17 billion. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. It currently has negative earnings. The firm also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father.

Natera, Inc. (NASDAQ:NTRA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.